B. Riley Financial Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals (NASDAQ:ETON) had its target price increased by analysts at B. Riley Financial from $26.00 to $31.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley Financial’s price target indicates a potential upside of 36.65% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen cut Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday. Finally, HC Wainwright increased their price target on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $39.33.

Eton Pharmaceuticals Stock Up 9.2%

Shares of Eton Pharmaceuticals stock traded up $1.92 during trading hours on Friday, hitting $22.69. The company had a trading volume of 523,179 shares, compared to its average volume of 282,471. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.63 and a quick ratio of 1.25. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00. The company has a market cap of $608.41 million, a P/E ratio of -90.74 and a beta of 1.19. The company’s 50-day moving average is $16.59 and its two-hundred day moving average is $17.34.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, March 19th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). The firm had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. Eton Pharmaceuticals had a negative return on equity of 11.32% and a negative net margin of 9.50%. Analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Deutsche Bank AG raised its holdings in Eton Pharmaceuticals by 4.9% in the fourth quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock valued at $309,000 after acquiring an additional 850 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Eton Pharmaceuticals by 11.1% in the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock worth $210,000 after acquiring an additional 1,244 shares during the period. Man Group plc raised its holdings in shares of Eton Pharmaceuticals by 6.0% during the second quarter. Man Group plc now owns 23,754 shares of the company’s stock valued at $338,000 after buying an additional 1,350 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of Eton Pharmaceuticals in the third quarter worth $30,000. Finally, Quarry LP bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth about $37,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Analysts’ price targets show substantial upside — the mean target implies roughly a 49% upside versus the current share price, and Zacks notes analyst upgrades in estimates that can support further gains. Read More.
• Positive Sentiment: Revenue strength / record top‑line growth: Eton reported record Q4 revenue and beat consensus revenue estimates modestly, which supports the narrative of accelerating commercial traction in its rare‑disease portfolio. Read More.
• Neutral Sentiment: Earnings call materials and summaries are available for investors to assess management’s commentary on growth drivers and commercialization plans. Review the call summary for color on guidance and product rollouts. Read More.
• Neutral Sentiment: The full earnings call transcript is posted for detailed read‑through of management’s remarks and Q&A, useful for judging sustainability of revenue trends. Read More.
• Negative Sentiment: EPS miss and ongoing unprofitability: Eton reported $0.05 EPS versus a $0.12 consensus (miss of $0.07) and still posts a negative net margin and negative ROE, highlighting that profitability and cost control remain concerns despite revenue growth. Read More.
• Negative Sentiment: Analysts and media flagged the EPS shortfall in standalone coverage, which can weigh on near‑term sentiment even as estimates get revised upward. Read More.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.